scholarly journals Intra-parenchymal brainstem haemorrhage secondary to iatrogenic needle injury after a parenteral injection in a cat

2016 ◽  
Vol 2 (1) ◽  
pp. 205511691663156
Author(s):  
Josep Brocal ◽  
Julien Guevar ◽  
Catherine Stalin ◽  
Alexane Durand ◽  
Rodrigo Gutierrez-Quintana
Keyword(s):  
Parenteral Injection

Prevention of experimental atherosclerosis by parenteral injection of atherogenic lipoproteins into newborn rabbits

1971 ◽  
Vol 71 (2) ◽  
pp. 113-114 ◽  
Author(s):  
Yu. N. Zubzhitskii ◽  
V. A. Nagornev ◽  
T. N. Lovyagina ◽  
�. B. Ban'kovskaya
Keyword(s):  
Experimental Atherosclerosis ◽  
Parenteral Injection

A case of accidental parenteral injection of Povan

1970 ◽  
Vol 16 (3) ◽  
pp. 740-742
Author(s):  
Alan G. Silverman ◽  
Howard I. Wilner ◽  
Ronald Okun
Keyword(s):  
Parenteral Injection

scholarly journals Quantitative determination of N-Acetyl cysteine by RP-HPLC method in bulk and parenteral injection

2018 ◽  
Vol 4 (5) ◽  
pp. 702-705 ◽  
Author(s):  
Sreenivasa Charan Archakam ◽  
Sridhar Chenchugari ◽  
Chandrasekhar Kothapalli Banoth
Keyword(s):  
Quantitative Determination ◽  
Hplc Method ◽  
Parenteral Injection ◽  
Rp Hplc ◽  
Acetyl Cysteine

scholarly journals Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn’s disease: a retrospective study

2021 ◽  
Vol 14 ◽  
pp. 175628482110430
Author(s):  
Hee Seung Hong ◽  
Kyuwon Kim ◽  
Kyunghwan Oh ◽  
Jae Yong Lee ◽  
Seung Wook Hong ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Oral Administration ◽  
Clinical Response ◽  
Activity Index ◽  
Medical Center ◽  
Retrospective Chart Review ◽  
Asian Population ◽  
Aminosalicylic Acid ◽  
Parenteral Injection

Introduction: Immunomodulators remain fundamental for the medical treatment of Crohn’s disease (CD). Methotrexate (MTX) is widely used as a second-line immunomodulator; however, there is a lack of recent data on MTX monotherapy among the Asian population with CD. Therefore, in this study, we aimed to investigate the tolerability and clinical outcomes of MTX in Korean patients with CD. Methods: A retrospective chart review was performed for CD patients treated with MTX monotherapy or in combination with 5-aminosalicylic acid (5-ASA), at the Asan Medical Center, Seoul, South Korea. The tolerability of MTX monotherapy within 6 months was assessed and the clinical effectiveness of MTX was evaluated based on the Crohn’s disease activity index (CDAI). Results: In total, 85 patients were included, of which 29 (34.1%) discontinued MTX due to intolerability during the follow-up. Adverse events (AEs) were reported in 41 (48.2%) patients. The most common AE was gastrointestinal disorders (17/41) and only one patient experienced a serious AE, a systemic infection that required hospitalization. Among the 56 patients who tolerated MTX within 6 months, 44 (65.9%) showed a clinical response. Moreover, no factor was significantly associated with intolerability. The administration method was the only factor significantly associated with a response to MTX ( p = 0.041). The adjusted odds ratio of parenteral injection compared to oral administration was 5.68 (95% confidence interval (CI), 1.07–30.08). Conclusion: In this study, one-third of patients were intolerant to MTX; nonetheless, the response rate was as high as 65.9% among tolerant patients. In addition, no significant factors affected intolerability. In terms of the clinical response, parenteral injection could be better than oral administration.

Parenteral injection of alcohol: Early warning of an emergent trend in Colombia?

2000 ◽  
Vol 18 (4) ◽  
pp. 351-363 ◽  
Author(s):  
J. Bryan Page ◽  
Maria José Míguez‐Burbano
Keyword(s):  
Early Warning ◽  
Parenteral Injection
Sign in / Sign up

Export Citation Format

Share Document